Learn About the Positive Results in Recent Phase 1/2 Clinical Trial

Modernizing the way medicines
are taken.

Focused on improving patient outcomes through our next generation drug delivery technology, the RITe™ Platform.
Rapid Infusion Technology™ (RITe) Platform
Extremely rapid disintegration. Enhanced absorption profiles. The RITe™ Platform is an advancement beyond the state-of-the-art in orally disintegrating and buccal tablet technologies, enabling a range of active ingredients to work quickly and efficiently in the body.
Explore our platform

RITe™ tablets disintegrate in less than 3 seconds, rapidly adhering to the absorption site and delivering an active ingredient through the tissue in your cheek.

  • Easy to take

    No water needed for RITe™ tablets

  • Fast action

    Effects felt in minutes

  • Enhanced bioavailability

    Same effects, lower dose

  • Patient experience icon

    Superior patient experience

    Addresses pain points of drug delivery

See all benefits
Our Lead Program: ORAVEXX™ (cannabidiol)

Introducing a non-addictive alternative to opioids for the management of pain and inflammation

Learn more about ORAVEXX™
Proprietary Manufacturing

All RITe™ products are manufactured at our state-of-the-art cGMP-compliant facility in New Jersey.

Orcosa exclusively controls all applications of the RITe™ Platform, which utilizes custom machinery to enable seamless scaled manufacturing.
Learn more
Research

Collaborating with Leading Research Institutions

We are empowering the medical community by partnering with leading research institutions and physicians to support FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to independently evaluate the safety and efficacy of CBD for the management of pain and inflammation.
Explore the trials

News

Statement on Enrollment of First Patient in NYU Langone Health’s Phase 2 Clinical Trial Utilizing ORAVAEXX™

July 22, 2022 – Orcosa is pleased to report the enrollment of the first patient participating in an investigator-initiated Phase 2 clinical trial utilizing ORAVEXX™ (cannabidiol, CBD) at NYU Langone Health Orthopedic Hospital (“NYU Langone”).  The trial (NCT05020028), an investigator-initiated randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU Langone, aims […]

Orcosa Appoints Andrew C. von Eschenbach, M.D. and Former Commissioner of the FDA, as Senior Advisor

July 14, 2022 EWING, N.J.–(BUSINESS WIRE)–Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Dr. Andrew C. von Eschenbach, former Commissioner of the U.S. Food and Drug Administration (“FDA”) as Senior […]

Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™

Infographic: Learn More About How the RITe™ Platform Works Infographic: Learn More About ORAVEXX™ Ewing, NJ – March 25, 2022 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced its […]

Statement on Final Patient Dosing in NYU Langone Health’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™

December 27, 2021 – Orcosa is pleased to report the dosing of the final patient participating in an investigator-initiated multicenter Phase 1/2 clinical trial utilizing ORAVEXX™ at NYU Langone Health Orthopedic Hospital (“NYU Langone”). The trial (NCT04672252), an investigator-initiated multicenter, randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU […]

View all